AB Science S.A (AB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AB Science S.A (AB) has a cash flow conversion efficiency ratio of 0.149x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.08 Million ≈ $-4.77 Million USD) by net assets (€-27.32 Million ≈ $-31.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AB Science S.A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
AB Science S.A - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how AB Science S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AB Science S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AB Science S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RENERGEN LTD CDI/1:1
F:996
|
N/A |
|
Euro India Fresh Foods Limited
NSE:EIFFL
|
0.020x |
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
N/A |
|
GaeaSoft Corp
KQ:051160
|
0.021x |
|
Ok Biotech Co Ltd
TW:4155
|
0.100x |
|
Data Communications Management Ltd
TO:DCM
|
0.347x |
|
Fortune Minerals Limited
TO:FT
|
0.105x |
|
Aureus Greenway Holdings Inc. Common Stock
NASDAQ:AGH
|
-0.016x |
Annual Cash Flow Conversion Efficiency for AB Science S.A (2009–2024)
The table below shows the annual cash flow conversion efficiency of AB Science S.A from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of AB Science S.A.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-23.75 Million ≈ $-27.77 Million |
€525.00K ≈ $613.78K |
-0.022x | -102.75% |
| 2023-12-31 | €-21.01 Million ≈ $-24.56 Million |
€-16.87 Million ≈ $-19.72 Million |
0.803x | +63.95% |
| 2022-12-31 | €-35.67 Million ≈ $-41.70 Million |
€-17.47 Million ≈ $-20.43 Million |
0.490x | -33.86% |
| 2021-12-31 | €-23.20 Million ≈ $-27.12 Million |
€-17.18 Million ≈ $-20.08 Million |
0.740x | +7.14% |
| 2020-12-31 | €-19.55 Million ≈ $-22.85 Million |
€-13.51 Million ≈ $-15.80 Million |
0.691x | +22.34% |
| 2019-12-31 | €-26.83 Million ≈ $-31.37 Million |
€-15.16 Million ≈ $-17.72 Million |
0.565x | -68.45% |
| 2018-12-31 | €-14.96 Million ≈ $-17.49 Million |
€-26.79 Million ≈ $-31.32 Million |
1.791x | +183.96% |
| 2017-12-31 | €10.73 Million ≈ $12.55 Million |
€-22.90 Million ≈ $-26.77 Million |
-2.133x | -129.94% |
| 2016-12-31 | €-4.71 Million ≈ $-5.50 Million |
€-33.52 Million ≈ $-39.19 Million |
7.124x | +431.03% |
| 2015-12-31 | €-17.26 Million ≈ $-20.18 Million |
€-23.16 Million ≈ $-27.07 Million |
1.342x | +48.59% |
| 2014-12-31 | €-15.68 Million ≈ $-18.33 Million |
€-14.16 Million ≈ $-16.55 Million |
0.903x | +102.40% |
| 2013-12-31 | €341.00K ≈ $398.66K |
€-12.84 Million ≈ $-15.01 Million |
-37.639x | -2868.84% |
| 2012-12-31 | €4.90 Million ≈ $5.73 Million |
€-6.21 Million ≈ $-7.26 Million |
-1.268x | -17.81% |
| 2011-12-31 | €7.73 Million ≈ $9.04 Million |
€-8.32 Million ≈ $-9.73 Million |
-1.076x | -102.33% |
| 2010-12-31 | €14.78 Million ≈ $17.28 Million |
€-7.86 Million ≈ $-9.19 Million |
-0.532x | +92.87% |
| 2009-12-31 | €1.04 Million ≈ $1.22 Million |
€-7.77 Million ≈ $-9.08 Million |
-7.460x | -- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more